Chaetocin: A promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress

Blood

Volumn 109, Issue 6, 2007, Pages 2579-2588

  Isham, Crescent R ^a   Tibodeau, Jennifer D ^a   Jin, Wendy ^a   Xu, Ruifang ^a   Timm, Michael M ^a   Bible, Keith C ^a,b  

^a Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CHETOCIN; DEXAMETHASONE; DISULFIDE; DOXORUBICIN; GLUTATHIONE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; INTERLEUKIN 6; NATURAL PRODUCT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; SYNDECAN 1; THALIDOMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; BONE MARROW CULTURE; CANCER PATIENT; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; DISULFIDE BOND; DRUG MECHANISM; DRUG SELECTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LEUKOCYTE; MOUSE; MULTIPLE MYELOMA; MYELOMA; MYELOMA CELL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL;

EID: 33947214077     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-07-027326     Document Type: Article

References (36)

1. Hauser D, Weber HP, Sigg HP. Isolation and configuration of Chaetocin. Helv Chim Acta. 1970;53:1061-1073.
2. Weber HP. The molecular structure and absolute configuration of chaetocin. Acta Cryst. 1972;B28:2945-2951.
3. Katagiri K, Sato K, Hayakawa S, Matsushima T, Minato H. Verticillin A, a new antibiotic from Verticillium sp. J Antibiot (Tokyo). 1970;23:420-422.
4. Dong JY, He HP, Shen Y-M, Zhang K-Q. Nematicidal Epipolysulfany- ldioxopiperazines from Gliocladium roseum. J Nat Prod. 2005;68:1510-1513.
5. Neuss N, Boeck LD, Brannon DR, et al. Aranotin and related metabolites from Arachniotus aureus (Eidam) Schroeter, IV: fermentation, isolation, structure elucidation, biosynthesis, and antiviral properties. Antimicrobial Agents Chemother. 1968;8:213-219.
6. Yamada A, Kataoka T, Nagai K. The fungal metabolite gliotoxin: immunosuppressive activity on CTL-mediated cytotoxicity. Immunol Lett. 2000;71:27-32.
7. Kawahara N, Nozawa K, Yamazaki M, Nakajima S, Kawai K. Structures of novel epipolythiodioxopiperazines, emethallicins B, C, and D, potent inhibitors of histamine release, from Emericella heterothallica. Chem Pharm Bull (Tokyo). 1990;38:73-78.
8. Chu M, Truumees I, Rothofsky ML, et al. Inhibition of c-fos proto-oncogene induction by Sch 52900 and Sch 52901, novel diketopiperazine produced by Gliocladium sp. J Antibiot (Tokyo). 1995;48:1440-1445.
9. Erkel G, Gehrt A, Anke T, Sterner O. Induction of differentiation in acute promyelocytic leukemia cells (HL-60) by the verticillin derivative Sch 52900. Z Naturforsch 2002;57c:759-767.
10. Kung AL, Zabludoff SD, France DS, et al. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell. 2004;6:33-43.
11. Vigushin DM, Mirsaidi N, Brooke G, et al. Gliotoxin is a dual inhibitor of farnesyltransferase and geranylgeranyltransferase I with antitumor activity against breast cancer in vivo. Med Oncol. 2004;21:21-30.
12. Wicklow D, Dowd P, Gloer J. Chaetomium mycotoxins with antiinsectan or antifungal activity. In: Kumagai S, ed. Mycotoxin Contamination: Health Risk and Prevention Project. Proceedings International Symposium on Mycotoxicology, Chiba, Japan, September 9-10, 1999. Tokyo, Japan: Matsumoto Printing; 1999:267-271.
13. Lavelle D, Chen YH, Hankewych M, DeSimone J. Histone deacetylase inhibitors increase p21(WAF1) and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression. Am J Hematol. 2001;68:170-178.
14. Mitsiades N, Mitsiades CS, Richardson PG, et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood. 2003;101:4055-4062.
15. Catley L, Weisberg E, Tai YT, et al. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003;102:2615-2622.
16. Khan SB, Maududi T, Barton K, Ayers J, Alkan S. Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma. Br J Haematol. 2004;125:156-161.
17. O'Connor OA, Heaney ML, Schwartz L, et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol. 2006;24:166-173.
18. Colletti SL, Myers RW, Darkin-Rattray SJ, et al. Broad spectrum antiprotozoal agents that inhibit histone deacetylase: structure-activity relationships of apicidin. Bioorg Med Chem Lett. 2001;11(pt 1):107-111.
19. Bible KC, Kaufmann SH. Flavopiridol (NSC 649890, L86-8275): a cytotoxic flavone that induces death in non-cycling A549 human lung carcinoma cells. Cancer Res. 1996;56:4856-4861.
20. Chai CL, Elix JA, Huleatt PB, Waring P. Scabrosin esters and derivatives: chemical derivatization studies and biological evaluation. Bioorg Med Chem. 2004;12:5991-5995.
21. Greenstein S, Krett NL, Kurosawa Y, et al. Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells. Exp Hematol. 2003;31:271-282.
22. Dalton WS, Durie BG, Alberts DS, Gerlach JH, Cress AE. Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res. 1986;46:5125-5130.
23. Bernardo PH, Brasch N, Chai CL, Waring P. A novel redox mechanism for the glutathione-dependent reversible uptake of a fungal toxin in cells. J Biol Chem. 2003;278:46549-46555.
24. Samulitis BK, Landowski TH, Dorr RT. Correlates of imexon sensitivity in human multiple myeloma cell lines. Leuk Lymphoma. 2006;47:97-109.
25. Kyle RA. Multiple myeloma and other plasma cell disorders. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, eds. Hematology Basic Principles and Practice. New York, NY: Churchill Livingstone; 1995:1354-1374.
26. Barlogie B, Tricot G, Rasmussen E, et al. Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and post-transplant consolidation therapies. Blood. 2006;107:2633-2638.
27. Fermand JP, Katsahian S, Divine M, et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol. 2005;23:9227-9233.
28. Blade J, Rosinol L, Sureda A, et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PET-HEMA. Blood. 2005;106:3755-3759.
29. Pelicano H, Carney D, Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist Updat. 2004;7:97-110.
30. Nakazato T, Ito K, Ikeda Y, Kizaki M. Green tea component, catechin, induces apoptosis of human malignant B cells via production of reactive oxygen species. Clin Cancer Res. 2005;11:6040-6049.
31. Evens AM, Lecane P, Magda D, et al. Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells. Blood. 2005;105:1265-1273.
32. Woo SH, Park IC, Park MJ, et al. Arsenic trioxide sensitizes CD95/Fas-induced apoptosis through ROS-mediated upregulation of CD95/Fas by NF-kappaB activation. Int J Cancer. 2004;112:596-606.
33. Chen Q, Chai YC, Mazumder S, et al. The late increase in intracellular free radical oxygen species during apoptosis is associated with cytochrome c release, caspase activation, and mitochondrial dysfunction. Cell Death Differ. 2003;10:323-334.
34. Pei XY, Dai Y, Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res. 2004;10:3839-3852.
35. Hodge DR, Peng B, Pompeia C, et al. Epigenetic silencing of manganese superoxide dismutase (SOD-2) in KAS 6/1 human multiple myeloma cells increases cell proliferation. Cancer Biol Ther. 2005;4:585-592.
36. Kuku I, Aydogdu I, Bayraktar N, Kaya E, Akyol O, Erkurt MA. Oxidant/antioxidant parameters and their relationship with medical treatment in multiple myeloma. Cell Biochem Funct. 2005;23:47-50.